Inovio Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
61.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$666.7Knext fiscal year
FY EPS (est.)
-$1.14next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| INO-3107 FDA PDUFA Target Action Date | 30 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Sufficiency Quarterly2KTarget: Extend beyond Q1 2027
INO-3107 BLA Regulatory Status QuarterlyTarget: FDA Approval by PDUFA date
Watch Items
- FDA Accelerated Approval Eligibility MeetingTrigger: FDA formal feedback on accelerated approval pathway eligibilityAction: Assess potential pivot to traditional approval pathway or additional clinical trial requirements
- INO-3107 PDUFA Target Action DateTrigger: October 30, 2026Action: Prepare commercial launch infrastructure or execute contingency plans if delayed
Research as of 19 Jun 2026